Skip to main content
OpenTrials
Completed

NCT Number: NCT06114576

Effects of Biofunctional Orange Juice on Cardiometabolic Risk Markers

The effects of orange juice enriched with vitamin D3 and encapsulated probiotics (Lacticaseibacillus casei Shirota and Lacticaseibacillus rhamnosus GG) compared to conventional orange juice on several cardiometabolic and anthropometric parameters in individuals at risk of cardiovascular disease.

Completed

Looking for future studies?

Notify Me

Key information

About this study

This randomized, double-blind, controlled clinical trial aims to evaluate the effects of the consumption of orange juice enriched with vitamin D3 and encapsulated probiotics (Lacticaseibacillus casei Shirota and Lacticaseibacillus rhamnosus GG) compared to conventional orange juice in 50 high cardiometabolic risk volunteers. The participants must be overweight/obese with either prediabetes, and/or hypertension, and/or hyperlipidemia, and will be divided and randomly assigned into 2 groups of 25 individuals each. Participants will consume 250 ml of either orange juice enriched with vitamin D3 and encapsulated probiotics (Lacticaseibacillus casei Shirota and Lacticaseibacillus rhamnosus GG) or conventional orange juice daily for 8 weeks as an addition to their usual dietary intake. Participants will be asked to maintain their usual physical activity during the intervention period. At the beginning of the study and at 8 weeks, blood samples will be collected after 12 hours of fasting. Two-hour oral glucose tolerance test (OGTT) will be performed using a continuous glucose monitoring system at the beginning and at 8 weeks. Anthropometric measurements will be performed at the beginning and every week for 8 weeks. Basal metabolic rate (BMR) and central aortic blood pressure will be measured at the beginning, 4 weeks, and 8 weeks of intervention. Fecal samples will be collected and analyzed to study gut microbiome compositob at the intervention's beginning and at 8 weeks.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Body Mass Index >= 25 kg/m2
  • Prediabetes [fasting blood glucose > 100 mg/dL], or/and
  • Hypertension [Systolic blood pressure (SBP) > 130 mmHg or Diastolic blood pressure (DBP) > 80 mmHg], or/and
  • Hyperlipidemia [total cholesterol > 200 mg/dL, and/or LDL-C > 100 mg/dL, and/or triglycerides > 150 mg/dL]

Exclusion criteria

  • Severe chronic disease (e.g. cardiovascular diseases, diabetes mellitus, kidney or liver diseases, endocrine conditions)
  • Medication that affects glycemia such as metformin, glucocorticoids, thiazide diuretics
  • Gastrointestinal disorders
  • Pregnancy
  • Lactation
  • Alcohol abuse
  • Drug dependency
  • Body weight lowering medications and/or history of bariatric surgery
  • Depression and other psychiatric diseases
  • Cancer
  • Probiotic, prebiotic, and vitamin D supplemental intake

Treatment and study plan

Orange juice enriched with vitamin D3 and encapsulated probiotics

Other

25 high cardiometabolic risk volunteers will be asked to consume 250 ml orange juice enriched with 2000 IU vitamin D3 and 10^8 cfu/ml encapsulated probiotics (Lactocaseibacillus casei shirota and Lactocaseibacillus rhamnosus GG) daily, for 8 weeks, without any other change in their dietary habits and physical activity.

Conventional orange juice

Other

25 high cardiometabolic risk volunteers will be asked to consume 250 ml conventional orange juice daily, for 8 weeks, without any other change in their dietary habits and physical activity.

Primary outcomes

  1. Change in blood glucose concentrations

    Time frame: 8 weeks

    Clinically significant change in blood glucose concentrations (mg/dL)

Secondary outcomes

  1. Change in energy intake

    Time frame: 8 weeks

    Clinically significant change in energy intake (kcal/day)

  2. Change in blood lipids

    Time frame: 8 weeks

    Clinically significant in triglycerides (mg/dL), total cholesterol (mg/dL), low-density lipoprotein (mg/dL), and high-density lipoprotein (mg/dL)

  3. Change in blood insulin concentrations

    Time frame: 8 weeks

    Clinically significant change in blood insulin concentrations (μU/L)

  4. Change in basal metabolic rate (BMR)

    Time frame: 8 weeks

    Clinically significant change in basal metabolic rate (kcal/day)

  5. Change in central aortic blood pressure

    Time frame: 8 weeks

    Clinically significant change in central pressure (mmHg)

  6. Change in body weight

    Time frame: 8 weeks

    Clinically significant change in body weight (kg)

  7. Change in gut microbiome

    Time frame: 8 weeks

    The microbial composition in fecal samples will be measured via taxonomic profiling by 16S (V3-V4 region) ribosomal RNA gene amplicon sequencing using the MiSeq Illumina platform (v3 300bp pair-end sequencing) to identify a wide diversity of microbes

Sponsors and collaborators

Lead sponsor

Agricultural University of Athens

Other

Registry information

Official study title

Effects of Orange Juice Enriched With Vitamin D3 and Encapsulated Probiotics in High Cardiometabolic Risk Individuals

Important dates

Study start
2023
Primary completion
2023
Study completion
2023
First posted
Nov 2, 2023
Registry last updated
Nov 2, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.